Acute Hypotensive States In Adult Patients — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute hypotensive states in adult patients. 36 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
36
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Acute Hypotensive States In Adult Patients

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 36 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute hypotensive states in adult patients. Each bar = one year. Y-axis scaled to peak year (21 patents).

6
35
21
38
4
39
5
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Levophed
Norepinephrine Bitartrate
 Pfizer Inc. 36 59 — 2035-02-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12097170 Levophed method of use 75 2041-03-08
12097170 Levophed method of use 75 2041-03-08
12097170 Levophed method of use 75 2041-03-08
10420735 Levophed method of use 70 2038-01-30
10226436 Levophed method of use 70 2038-01-30
10420735 Levophed method of use 70 2038-01-30
10226436 Levophed method of use 70 2038-01-30
11413259 Levophed method of use 70 2038-01-30
11413259 Levophed method of use 70 2038-01-30
10420735 Levophed method of use 70 2038-01-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10888534 Levophed formulation 50 2039-04-26
10888534 Levophed formulation 50 2039-04-26
10888534 Levophed formulation 50 2039-04-26
10159657 Levophed formulation 50 2038-01-30
11602508 Levophed formulation 50 2038-01-30
10568850 Levophed formulation 50 2038-01-30
11602508 Levophed formulation 50 2038-01-30
10159657 Levophed formulation 50 2038-01-30
10159657 Levophed formulation 50 2038-01-30
10568850 Levophed formulation 50 2038-01-30

Related